ImmuCell Corporation (ICCC)

ImmuCell Corporation is a NASDAQ-listed common stock of a healthcare company focused on animal health. The company develops, manufactures, and sells products intended to improve the health and productivity of dairy and beef cattle in the United States and international markets. Its business is organized into two segments, Scours and Mastitis. Key products include First Defense, an oral scours preventive for calves with claims against E. coli, coronavirus, and rotavirus; Tri-Shield First Defense, a passive antibody treatment for the same pathogens; California Mastitis Test, an on-farm diagnostic used to identify mastitis through somatic cell counts in milk; and Dual-Force First Defense, a bivalent gel tube formulation. ImmuCell is also developing Re-Tain Drug Product, a nisin-based intramammary treatment for subclinical mastitis in lactating dairy cows. The company distributes its products through animal health distributors and is headquartered in Portland, Maine.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.